Platform to analyze and understand ALS

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

CAPTURE ALS is a long-term observational platform designed to collect and analyze extensive data on Amyotrophic Lateral Sclerosis (ALS) and related disorders. Participants will undergo up to five in-person visits over a year, where they will receive clinical evaluations, neurocognitive and speech testing, and MRI scans. Healthy controls will also participate for comparison purposes. The collected biospecimens and data will be stored in a biorepository and made available to researchers globally to advance ALS research.

Why it matters

Who can join: the full rules

\[PATIENTS\]

Inclusion Criteria:

1. Has ALS, classified as definite, probable, laboratory-supported probable, or possible ALS according to the revised El Escorial criteria or a related neurodegenerative disorder including ALS-FTD, PLS, PMA or asymptomatic individuals with a known ALS mutation (as previously confirmed during regular clinical care)
2. Be of the age of majority in their province of residence/treatment
3. Have the cognitive capacity to provide informed consent
4. Have proficiency in English or French in order to understand study instructions and respond to questionnaires

Exclusion Criteria:

N/A

\[HEALTHY CONTROLS\]

Inclusion Criteria:

1. Be between the ages of 40-80 unless age matched to a patient (+/-3 years) who is already enrolled
2. Be the age of majority in their province of residence/treatment
3. Have the cognitive capacity to provide informed consent
4. Have proficiency in English of French to understand study instructions and respond to questionnaires

Exclusion Criteria:

1. A history of a neurological disease, including Central Nervous System disease (e.g., stroke, head injury, epilepsy) or Peripheral Nervous System disease (neuropathy, myopathy)
2. A history of psychiatric disease (e.g. depression, bipolar disease) that is clinically diagnosed and/or with the current use of psychiatric medications (e.g. antidepressants) for an indication of a psychiatric disease.
3. Subjects ineligible for an MRI due to a pacemaker or other contraindication according to local MRI policies of the study centre.
4. Significant claustrophobia that would prohibit an MRI (subjects will be required to lie in an MRI scanner for approximately one hour).

Where it's running

• University of Alberta
  Edmonton, Alberta, Canada Recruiting
• University of Toronto / Sunnybrook Health Sciences Centre
  Toronto, Ontario, Canada Recruiting
• McGill University / Montreal Neurological Institute and Hospital
  Montreal, Quebec, Canada Recruiting
• CHU de Quebec -Universite de Laval
  Québec, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Sanjay Kalra, MD — University of Alberta
• Study coordinator: Claire Magnussen, PhD
• Email: info@captureals.ca
• Phone: 514-398-6188

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Research to gather clinical data on ALS and related disorders

  This study is collecting health information from people with ALS and similar disorders to better understand these conditions and help improve future treatments.

  Recruiting at 10 sites University of Miami · Irvine, California and 10 other locations · NCT03489278

• MRI markers for ALS and PLS

  The study will use 3T and 7T MRI scans to see if specific brain imaging markers differ between people with ALS or PLS and healthy volunteers.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT02567136

• Implanted Brain-Computer Interface to Help People with Severe Arm Impairment

  We’re testing the N1 System, a fully implanted brain interface in the motor cortex with a robot, to see if it can help adults with spinal cord injury, ALS, or chronic stroke use a computer or keyboard more easily.

  Recruiting Neuralink Corp · Miami, Florida · NCT07929792

• Brain-computer interface chat tool for people with ALS

  This test compares a wearable brain-computer interface communication device to eye-tracking devices that people with ALS currently use to help them communicate.

  Recruiting Cognixion · Santa Barbara, California · NCT07871071

• BIIB147 safety and how it behaves in adults with ALS

  This study tests BIIB147 in adults with ALS to see if it is safe and how the body handles it, including early and long-term effects.

  Recruiting at 2 sites Phase 1/2 Biogen · St Louis, Missouri and 1 other locations · NCT07855211

• Aims to restore UNC13A function in people with ALS

  This trial tests TRCN-1023 in adults with ALS to see if it’s safe, tolerated, and shows early signs of benefit.

  Recruiting at 6 sites Phase 1/2 Trace Neuroscience, Inc. · Lübeck, Schleswig-Holstein and 5 other locations · NCT07674667

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.